Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Is Global Partners (GLP) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:45pm, Monday, 09'th Mar 2026
Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.
Global Partners (GLP) Upgraded to Buy: Here's Why
01:00pm, Monday, 09'th Mar 2026
Global Partners (GLP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Omada Health: GLP-1-Focused Telehealth Platform Users May Feel They Can Do Without
08:15am, Monday, 09'th Mar 2026
Omada Health targets enterprise GLP-1 companion care, leveraging its platform to manage high employer demand for GLP-1 drugs. 2025 revenues grew 53% to $260M; 2026 guidance implies 22% topline growth
Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet(TM)
07:40am, Monday, 09'th Mar 2026
GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301 Proprietary Forzet formulation provides pharmacists, physicians and patients with unique solution for GLP-1 drugs' primary sid
Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce
10:56am, Saturday, 07'th Mar 2026
In a dramatic reversal of fortune, Hims & Hers Health ( NYSE:HIMS ) has been rescued by the very company that nearly sank it.
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?
06:05pm, Friday, 06'th Mar 2026
Novo Nordisk shares look cheap, but execution and management changes weigh on investor confidence. Eli Lilly's stronger GLP-1 growth and consistency support its premium versus Novo's conditional value
Omada Health Announces GLP-1 Flex Care, Giving Employers a New, Flexible Path to Support Obesity Care
04:07pm, Thursday, 05'th Mar 2026
SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first provider of between-visit care, today announced GLP-1 Flex Care, a new offering that will support emplo
GLP-1 drugs protect against new or worsening addictions, large study shows
06:36pm, Wednesday, 04'th Mar 2026
Ozempic, Mounjaro and other GLP-1 drugs for diabetes can prevent the formation of new substance use disorders and alleviate existing addictions, according to findings from a large study of U.S. mil
Midstream Energy: Relative Favorability
01:56am, Wednesday, 04'th Mar 2026
Twenty-nine midstream energy companies were evaluated on a relative favorability matrix with factors representing yield, yield coverage, valuation, profitability, growth, and leverage. Based on this a
Hims & Hers Health: Leaving GLP-1s Behind
10:57am, Tuesday, 03'rd Mar 2026
Hims & Hers (HIMS) remains a 'Strong Buy' at $16, with fair value estimated at $22 despite recent headwinds. International expansion via the $1.15B Eucalyptus acquisition and product diversification a
Hims' pharmacy partner will reintroduce GLP-1 pill pulled from market, Endpoints News reports
10:40am, Tuesday, 03'rd Mar 2026
Hims & Hers Health's pharmacy partner, Strive Pharmacy, plans to resume sales of its compounded weight‑loss pill through other healthcare providers after halting distribution following U.S. re
As oral GLP-1s enter the market with slightly more modest weight and glycemic outcomes than injectable formulations, Dario integrates structured behavioral reinforcement to optimize real-world success
Is Novo Nordisk's GLP-1 Dominance Fading After Lilly's Clinical Wins?
10:02am, Monday, 02'nd Mar 2026
NVO shares plunge 21% after Lilly's Zepbound and oral orforglipron beat its key GLP-1 drugs in head-to-head obesity and diabetes studies, respectively.
Hims expansion may not come in time for risky GLP-1 business
09:16am, Monday, 02'nd Mar 2026
Telehealth company Hims & Hers Health , known for its weight-loss drug business, is promising it can diversify away from its reliance on compounded GLP-1 sales in the U.S., but that may not happen soo
Global Partners LP Files 2025 Annual Report on Form 10-K
04:05pm, Friday, 27'th Feb 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that its Annual Report on Form 10-K for the year ended December 31, 202
